Elemis sold: PAI Partners buys skincare brand from L'Occitane

The European private equity firm PAI Partners has agreed to buy the British skincare brand Elemis from L'Occitane Group, the companies announced on Wednesday, 4 November 2026. The price was not disclosed. The deal is expected to close in the first quarter of 2027, subject to regulatory approvals and other usual closing conditions. It ends L'Occitane's seven-year ownership of the brand, which it bought in 2019 for about $900 million.

The sale is a clear example of how the beauty industry is being reshaped by investors. Large groups that collected many brands over the past decade are now choosing which ones to keep, while private equity firms, which buy companies with investors' money and aim to grow them before selling again, are paying for brands that already have loyal buyers. Reinold Geiger, chairman and chief executive of L'Occitane, described the sale as "a disciplined portfolio decision, focused on long-term value creation for the Group".

Elemis is also a brand with a woman at its head who has stayed through several changes of owner. Noella Gabriel, who co-founded the company in 1989, remains chief executive. In her statement she thanked L'Occitane for its support over seven years and said the brand was moving into its next phase of growth with PAI. That continuity matters in beauty, where a founder's product knowledge and the trust of spa therapists and customers are part of what an investor is buying.

The brand's growth explains the interest. Its best-known line is the Pro-Collagen skincare range, and the company says its products combine biotechnology with natural ingredients. Its sales nearly doubled under L'Occitane, reaching more than $300 million in fiscal 2026, and it has become far more dependent on the American market and on online selling. PAI's two partners on the deal, Gaëlle d'Engremont and Colm O'Sullivan, pointed to the brand's "clinically proven performance". That is the company's own description of its products and has not been independently tested for this story.

Because the price was not published, outside analysts have tried to estimate it. Drew Fallon, co-founder and chief executive of the finance firm Iris Finance, estimated Elemis's value at about $1.13 billion, or 3.7 times its roughly $306 million in sales, based on other beauty deals. This is his estimate, not a figure from either company.

For Indian readers following the beauty business, the deal shows what investors reward: a premium skincare range with clear product lines, strong online sales and a large overseas market. Indian brands seeking investment face the same questions about where their sales come from and how much depends on one market.

Peepals calculation: If Elemis is worth the $1.13 billion that one analyst estimates, that would be about 26% more than the roughly $900 million L'Occitane paid in 2019 (1,130 ÷ 900 ≈ 1.26). With the US at about half of roughly $306 million in sales, American buyers account for something like $150 million a year (306 × 0.5 ≈ 153). Our calculation from the reported figures.

Short-term: Nothing changes for shoppers until the deal closes, expected in the first quarter of 2027. Regulators still have to approve it, and L'Occitane remains the owner until then.

Long-term: PAI says it will push harder into the US, open more international markets, invest in digital selling and selected premium shops, and develop the Pro-Collagen range. Private equity owners usually aim to sell a business again after several years, so Elemis may change hands once more in future.

Who is affected: Elemis staff and its co-founder Noella Gabriel, spa and retail partners, L'Occitane's shareholders, and other skincare brands that may now attract buyers.

What to watch next: The deal's closing, expected in the first quarter of 2027 once regulators approve it.

Questions and Answers